Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU)…
27 Apr 2026
UK biotech could be bound for recovery, BIA report reveals
New data debuted by the UK’s BioIndustry Association (BIA) has hinted towards the recovery of the British biotech financing market, which an expert says could help shift attention away from…
27 Apr 2026
Sun Pharma to acquire Organon for $11.75bn
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, paying $14.00 per share for all outstanding shares. Organon, created…
24 Apr 2026
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The European drug market could soon be poised to receive three new entries, as the European Committee for Healthcare and Medicinal Products (CHMP) has recommended drugs by Novartis, Arrowhead Pharmaceuticals…
24 Apr 2026
OZMOSI and Planview partner to enhance pharmaceutical data integration
OZMOSI and Planview have formed a partnership to support pharmaceutical organisations by integrating Ozmosi’s structured, machine-readable clinical datasets with Planview’s AI-driven portfolio planning platform. The initiative aims to link external…
24 Apr 2026
Regeneron cuts White House pricing deal, offers new gene therapy for free
It’s been a busy few days for Regeneron Pharmaceuticals, which has inked a drug pricing agreement with the White House, while pledging to offer its newly approved rare hearing loss…
24 Apr 2026
Cumberland to sell drug portfolio to Apotex for $100m
Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canadian pharmaceutical company Apotex for $100m in cash. Under the agreement, Apotex will acquire Cumberland's branded medicines for…